Nivolumab Ups Overall Survival in Head, Neck Cancer

This article originally appeared here.
Share this content:
Nivolumab Ups Overall Survival in Head, Neck Cancer
Nivolumab Ups Overall Survival in Head, Neck Cancer

MONDAY, Oct. 10, 2016 (HealthDay News) -- Nivolumab is associated with longer overall survival than standard single-agent therapy in patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, according to a study published online Oct. 9 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Medical Oncology Congress, held from Oct. 7 to 11 in Copenhagen, Denmark.

Robert L. Ferris, M.D., Ph.D., from the University of Pittsburgh Medical Center and Cancer Institute, and colleagues conducted a randomized trial involving 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within six months after platinum-based chemotherapy. Patients were randomized in a 2:1 ratio to nivolumab every two weeks or a standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab).

The researchers found that the median overall survival was 7.5 and 5.1 months in the nivolumab and standard therapy groups, respectively. Overall survival was significantly longer with nivolumab (hazard ratio for death, 0.70; 97.73 percent confidence interval, 0.51 to 0.96); the estimates of one-year survival were 36.0 versus 16.6 percent for nivolumab versus standard therapy. The median progression-free survival was 2.0 and 2.3 months for nivolumab and standard therapy, respectively (hazard ratio for disease progression or death, 0.89; 95 percent confidence interval, 0.70 to 1.13).

"Treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy," the authors write.

The study was funded by Bristol-Myers Squibb, the manufacturer of nivolumab.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ultraviolet B Radiation Exposure Tied to Decreased Risk of Myopia

Ultraviolet B Radiation Exposure Tied to Decreased Risk ...

More exposure to sun's UVB rays between ages 14 and 29 linked to lower risk

Vitamin D in Pregnancy Might Help Prevent MS in Offspring

Vitamin D in Pregnancy Might Help Prevent MS ...

Infants born with low levels of vitamin D may be more likely to develop multiple sclerosis later in life

Dabigatran May Be Better Than Warfarin After Bleeding Episode

Dabigatran May Be Better Than Warfarin After Bleeding ...

Resuming any anticoagulant found safer than stopping the drugs in these cases

is free, fast, and customized just for you!

Already a member?

Sign In Now »